Press Releases

10.08.2017

• Results from the TEACH (HIV) and IMPULSE (small cell lung cancer) clinical trials with lefitolimod • Completion of patient recruitment for the IMPALA pivotal study (colorectal cancer) • Promising results obtained from pre-clinical combination...

09.08.2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced the key results of the extension phase of the exploratory phase Ib/IIa TEACH trial to evaluate lefitolimod in HIV-positive (HIV:...

15.05.2017

Berlin, 15 May 2017 – The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) has achieved the recruitment goal with the inclusion of currently 540 patients for the pivotal IMPALA study in...

11.05.2017

• Ongoing implementation of the “Next Level” corporate strategy • Funding secured until the start of 2018 through additional capital measure • Further progress in clinical studies with lead product lefitolimod • Preparations for possible...

24.04.2017

- Clinically relevant subgroups benefit from the treatment with lefitolimod in this study - Results are indicative for the further development of lefitolimod in SCLC

22.03.2017

• Ongoing implementation of the new “Next Level” corporate strategy • Funding secured until the start of 2018 through capital measures • Lead product lefitolimod: significant milestones reached • Changes to Executive Board • Confident...

27.02.2017

The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today first combination data of its TLR9 agonists EnanDIM® with a checkpoint inhibitor.

   

Displaying results 1 bis 7 von 12

Page 1

Page 2

next

   

Positive subgroup results IMPULSE study

Press Release
Presentation

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.